Dr. Ting Niu: Population-based study reveals prognostic factors and clinical characteristics of gray zone lymphoma patients

Dr. Ting Niu: Population-based study reveals prognostic factors and clinical characteristics of gray zone lymphoma patients

2024.01.16
From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) annual conference was held grandly in Frankfurt, Germany. The EHA conferences have always been spectacular, with research on lymphoma consistently attracting significant attention. A study on gray zone lymphoma by Dr Ting Niu's team from West China Hospital of Sichuan University ( Abstract No.: P1198) was selected for this EHA. The research aimed to summarize the clinical characteristics and factors influencing the prognosis of gray zone lymphoma by reviewing the relevant data in the SEER database. To gain a deeper understanding of the research, Oncology Frontier invited Dr Niu to provide aninterpretation as  below.
Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases  at 2023 EHA  

Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases  at 2023 EHA  

2024.01.16
The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children's Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of research, including the prognostic factors for relapsed childhood acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol in China, the use of Blinatumomab for 14 days in combination with chemotherapy to achieve minimal residual disease (MRD) conversion in pediatric B-ALL patients, the integration of transcriptomic features to improve prognosis prediction in pediatric acute myeloid leukemia (AML) with KMT2A rearrangements, and the effective treatment of pediatric non-sickle cell anemia (NSAA) with Hydroxyurea in combination with CSA. To gain a deeper understanding of these studies, Dr. Zhu has provided interpretations of the research findings, which are summarized below.
Dr. Huiqiang Huang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.

Dr. Huiqiang Huang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.

2024.01.16
Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt, Germany. A selected oral report (Abstract No.: S226) from the conference showed that the use of PD-1 inhibitors alone or in combination significantly improved the treatment of R/R ENKTCL patients. This study further confirmed that immune checkpoint inhibitors have become an important treatment option for R/R ENKTCL patients. Oncology Frontier invited Dr. Huiqiang Huang from Sun Yat-sen University Cancer Center to share the research findings and insights at the conference.
Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

2024.01.16
The annual European Hematology Association (EHA) conference was recently held in Frankfurt, Germany, in a hybrid online and offline format. As the largest international conference in the European hematology field, the EHA meeting covered a wide range of scientific topics, clinical and basic research, including benign and malignant hematology, discussing the latest developments in the field of hematology. At this EHA conference, a study (abstract S224) by the team of Professor Ryan Jacobs from the Atrium Health Levine Cancer Institute in the U.S. explored the value of TNB-486 (targeting CD19/CD3) in the treatment of relapsed/refractory follicular lymphoma and achieved impressive results. As a result, Oncology Frontier interviewed Professor Ryan Jacobs on-site for a detailed interpretation of the latest developments in the treatment of follicular lymphoma and diffuse large B-cell lymphoma.
Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia

Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia

2024.01.16
T-cell lymphoblastic lymphoma (T-LBL) is a highly malignant and rare lymphoma with aggressive behavior. It primarily affects adolescents, often presenting with mediastinal lymph node enlargement and commonly accompanied by pericardial and pleural effusions. In some cases, the disease can involve the central nervous system (CNS) with neurological manifestations. About 20% of patients progress to acute T-cell lymphoblastic leukemia (T-ALL) in advanced stages, which has a rapid progression and poor prognosis.